株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

カンジダ症:パイプライン分析

Candidiasis - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 192515
出版日 ページ情報 英文 161 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
カンジダ症:パイプライン分析 Candidiasis - Pipeline Review, H2 2017
出版日: 2017年08月22日 ページ情報: 英文 161 Pages
概要

カンジダ症は、主にカンジダアルビカンスという種類のカンジダ属による感染によって引き起こされます。皮膚のカンジダ感染症では、特徴がはっきりした紅斑が見られ、皮膚のかゆみ、多くの場合は体液漏出があります。かさぶた、膿疱が見られることもあります。通常、鼠径部・臀部の内側などに見られ、胸の谷間、足指の間、手指の間、臍帯などにも見られます。治療には、抗真菌薬などが含まれます。

当レポートでは、カンジダ症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

カンジダ症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 未確認段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Amplyx Pharmaceuticals, Inc.
  • Bakker Medical Srl
  • Biomar Microbial Technologies
  • Cellceutix Corporation
  • Cidara Therapeutics, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • General Biologicals Corporation
  • Grupo Ferrer Internacional, S.A.
  • Hsiri Therapeutics, LLC
  • Nanomerics Ltd
  • Novabiotics Limited
  • NovaDigm Therapeutics, Inc.
  • Onxeo SA
  • Panacela Labs, Inc.
  • Scynexis, Inc.
  • Sealife PHARMA GMBH
  • TGV-Laboratories
  • Viamet Pharmaceuticals, Inc.
  • Wellstat Vaccines, LLC

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • 61894700
  • AC-17
  • amphotericin b
  • amphotericin B
  • amphotericin B
  • APX-001
  • arasertaconazole
  • Candida vaccine
  • candidiasis vaccine
  • CD-101
  • CTIX-1502
  • DWP-06081
  • Forazoline A
  • KSL-W
  • MH-010
  • miconazole nitrate
  • Monoclonal Antibodies to Target Fba for Candidiasis
  • mutanobactins
  • Myc-102
  • NDV-3
  • NDV-3A
  • NP-339
  • obliquumol
  • PAC-113
  • pegylated amphotericin B
  • PMX-1408
  • PMX-1570
  • PMX-1576
  • PMX-1591
  • PMX-1625
  • PMX-519
  • PMX-70004
  • Prof-002
  • 口腔咽頭カンジダ症用組換型ペプチド
  • SCY-078
  • SLP-0901
  • SLP-0904
  • 細菌性膣炎・カンジダ症用小分子
  • 全身性カンジダ症用小分子
  • アスペルギルス症・カンジダ症用小分子
  • カンジダ症用小分子
  • 真菌感染症用小分子
  • 多剤耐性細菌感染症用合成ペプチドSynthetic
  • VT-1161
  • XELRYX-3

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9643IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Pipeline Review, H2 2017, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.

Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 7, 2, 22, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 9 molecules, respectively.

Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Candidiasis - Overview
    • Candidiasis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Candidiasis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Candidiasis - Companies Involved in Therapeutics Development
    • Amplyx Pharmaceuticals Inc
    • Bakker Medical Srl
    • Beta Pharma Inc
    • Biomar Microbial Technologies
    • Bionex Pharmaceuticals LLC
    • Biosergen AS
    • Cidara Therapeutics Inc
    • Dermala Inc
    • Gedea Biotech AB
    • General Biologicals Corp
    • Grupo Ferrer Internacional SA
    • Hsiri Therapeutics LLC
    • iCo Therapeutics Inc.
    • ImmunoClin Corp
    • Matinas BioPharma Holdings Inc
    • Nanomerics Ltd
    • Novabiotics Ltd
    • NovaDigm Therapeutics Inc
    • Novartis AG
    • Onxeo SA
    • Scynexis Inc
    • Sealife PHARMA GMBH
    • Viamet Pharmaceuticals Inc
    • Visterra Inc
    • Wellstat Vaccines LLC
    • Candidiasis - Drug Profiles
  • (clotrimazole + diclofenac sodium) - Drug Profile
    • 61894700 - Drug Profile
    • AC-17 - Drug Profile
    • amphotericin B - Drug Profile
    • amphotericin B - Drug Profile
    • amphotericin B - Drug Profile
    • Amphotericin B sodium - Drug Profile
    • Antibody to Target Ece1 for Candidiasis - Drug Profile
    • APX-001 - Drug Profile
    • APX-001A - Drug Profile
    • arasertaconazole - Drug Profile
    • B-4010 - Drug Profile
    • BL-5923 - Drug Profile
    • BSG-005 - Drug Profile
    • candidiasis vaccine - Drug Profile
    • CD-101 - Drug Profile
    • Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
    • CLX-159 - Drug Profile
    • CSA-13 - Drug Profile
    • Drug for Candidiasis - Drug Profile
    • Drug for Oral Candidiasis - Drug Profile
    • Forazoline A - Drug Profile
    • GA-101 - Drug Profile
    • iCo-010 - Drug Profile
    • interleukin-22 - Drug Profile
    • JSM-11 - Drug Profile
    • KSL-W - Drug Profile
    • miconazole nitrate - Drug Profile
    • Monoclonal Antibodies for Candidiasis - Drug Profile
    • Monoclonal Antibody for Candidiasis - Drug Profile
    • Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections - Drug Profile
    • mutanobactin A - Drug Profile
    • NDV-3 - Drug Profile
    • NDV-3A - Drug Profile
    • NP-339 - Drug Profile
    • obliquumol - Drug Profile
    • Occidiofungin - Drug Profile
    • P-113Du - Drug Profile
    • P-113Tri - Drug Profile
    • PAC-113 - Drug Profile
    • Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile
    • Prof-002 - Drug Profile
    • Recombinant Enzyme for Candidiasis - Drug Profile
    • Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile
    • SCY-078 - Drug Profile
    • SLP-0901 - Drug Profile
    • SLP-0904 - Drug Profile
    • Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
    • Small Molecule for Candidiasis - Drug Profile
    • Small Molecule for Fungal Infections - Drug Profile
    • Small Molecules for Aspergillosis and Candidiasis - Drug Profile
    • Small Molecules for Candidiasis - Drug Profile
    • Small Molecules for Candidiasis - Drug Profile
    • Small Molecules for Candidiasis - Drug Profile
    • Small Molecules for Fungal Infections - Drug Profile
    • Small Molecules for Fungal Infections - Drug Profile
    • Small Molecules for Systemic Candidiasis - Drug Profile
    • Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile
    • Synthetic Peptides for Candidiasis - Drug Profile
    • Synthetic Peptides for Infections Diseases and Oncology - Drug Profile
    • TOL-463 - Drug Profile
    • Vaccine to Target Ece1 for Candidiasis - Drug Profile
    • Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile
    • VIS-FNG - Drug Profile
    • voriconazole - Drug Profile
    • VT-1129 - Drug Profile
    • VT-1161 - Drug Profile
    • VT-1598 - Drug Profile
  • Candidiasis - Dormant Projects
  • Candidiasis - Discontinued Products
  • Candidiasis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Candidiasis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Candidiasis - Pipeline by Amplyx Pharmaceuticals Inc, H2 2017
  • Candidiasis - Pipeline by Bakker Medical Srl, H2 2017
  • Candidiasis - Pipeline by Beta Pharma Inc, H2 2017
  • Candidiasis - Pipeline by Biomar Microbial Technologies, H2 2017
  • Candidiasis - Pipeline by Bionex Pharmaceuticals LLC, H2 2017
  • Candidiasis - Pipeline by Biosergen AS, H2 2017
  • Candidiasis - Pipeline by Cidara Therapeutics Inc, H2 2017
  • Candidiasis - Pipeline by Dermala Inc, H2 2017
  • Candidiasis - Pipeline by Gedea Biotech AB, H2 2017
  • Candidiasis - Pipeline by General Biologicals Corp, H2 2017
  • Candidiasis - Pipeline by Grupo Ferrer Internacional SA, H2 2017
  • Candidiasis - Pipeline by Hsiri Therapeutics LLC, H2 2017
  • Candidiasis - Pipeline by iCo Therapeutics Inc., H2 2017
  • Candidiasis - Pipeline by ImmunoClin Corp, H2 2017
  • Candidiasis - Pipeline by Matinas BioPharma Holdings Inc, H2 2017
  • Candidiasis - Pipeline by Nanomerics Ltd, H2 2017
  • Candidiasis - Pipeline by Novabiotics Ltd, H2 2017
  • Candidiasis - Pipeline by NovaDigm Therapeutics Inc, H2 2017
  • Candidiasis - Pipeline by Novartis AG, H2 2017
  • Candidiasis - Pipeline by Onxeo SA, H2 2017
  • Candidiasis - Pipeline by Scynexis Inc, H2 2017
  • Candidiasis - Pipeline by Sealife PHARMA GMBH, H2 2017
  • Candidiasis - Pipeline by Viamet Pharmaceuticals Inc, H2 2017
  • Candidiasis - Pipeline by Visterra Inc, H2 2017
  • Candidiasis - Pipeline by Wellstat Vaccines LLC, H2 2017
  • Candidiasis - Dormant Projects, H2 2017
  • Candidiasis - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Candidiasis - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Candidiasis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Candidiasis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top